Calretinin expression in molecular subtypes of invasive carcinoma breast

Suryagayathri Venugopal, Cicy P. J., Deepa S., Sankar Sundaram


Background: Breast cancer is a leading cause of cancer death  in women worldwide. Breast carcinoma is currently managed by assessing clinicopathological features. Elucidation of molecular mechanisms of pathogenesis of breast carcinoma  may lead to the development of new targeted therapies, particularly in triple negative cancers. Literature shows a few studies on the expression of calretinin  in breast carcinoma particularly in basal like type and its prognostic significance.  In this study, authors are trying  to assess the expression of  a new marker calretinin in different molecular subtypes of invasive carcinoma breast.

Methods: This study was done in  107 cases of invasive carcinoma breast specimens received in  Department of Pathology, Government Medical college, Kottayam from December  2017 to May 2019.

Results: Among the molecular subtypes, Basal like tumours showed 68.4% of cases with high level and 31.6% of cases with low level calretinin expression which is comparable with the study by Farrag et al. All the other molecular subgroups showed predominantly low level of calretinin expression.

Conclusions: Different molecular subtypes of invasive carcinoma breast showed varied calretinin expression. High level calretinin expression was significantly associated with grade 3 (p value = 0.002), ER negativity (p = 0.004), PR negativity (p = 0.018)  and Basal like molecular subtype (p : <0.001). This suggests that calretinin might play a role in pathogenesis of basal like breast carcinomas.


Calretinin, Invasive carcinoma, Molecular subtype

Full Text:



Consensus document for management of Breast cancer; 2016. Available at: Accessed 20 September 2019.

Malvia, S, Bagadi, S. A, Dubey, U. S. and Saxena, S. Epidemiology of breast cancer in Indian women. Asia-Pac J Clin Oncol. 2017;13:289-95.

Dai X, Xiang L, Li T, Bai Z. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Canc. 2016;7(10):1281-94.

Colditz G, Chia KS, Invasive breast carcinoma: Introduction and general features. Sunil R. Lakhani, IanO. Ellis, editors. WHO classification of tumors–WHO classification of tumors of the Breast. Lyon. IARC press. 2012;14-23.

Farrag MS, El-karef AA, Amin MM, Helal NM, Ali OF, Farrag NS. Calretinin expression as a reliable prognostic marker in different molecular subtypes of breast carcinoma. Ind J Pathol Microbiol. 2017;60:8-14.

Rogers JH. Calretinin: a gene for a novel calcium binding protein expressed principally in neurons. J Cell Biol. 1987;105:1343-53.

Badowska-Kozakiewicz AM, Budzik MP. Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol. 2016;20(6):436-43.

Wolff AC, Hammond ME, Allison KH, Harvey BE, Mangu PB, Bartlett JM, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364-82.

Aboobacker KK, Saldanha P. Expression of mesothelial marker calretinin in breast cancer. Int J Innovat Res Med Sci. 2019: 04(01): 87-92.

Taliano RJ, Lu S, Singh K, Mangray S, Tavares R, Noble L, et al. Calretinin expression in high grade invasive ductal carcinoma of the breast is associated with basal like subtype and unfavorable prognosis. Hum Pathol. 2013;44:2743-50.

Powell G, Roche H, Roche WR. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. Histopathol. 2011;59:950-6.